<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01391117</url>
  </required_header>
  <id_info>
    <org_study_id>CR017992</org_study_id>
    <secondary_id>TMC649128HPC1002</secondary_id>
    <nct_id>NCT01391117</nct_id>
    <nct_alias>NCT01532557</nct_alias>
  </id_info>
  <brief_title>TMC649128HPC1002 - a Trial inGenotype 1 Hepatitis C Virus (HCV) - Infected Participants to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of TMC649128, Alone and Combined With Pegylated Interferon + Ribavirin</brief_title>
  <official_title>A Phase Ib, Double-Blind, Randomized, Placebo-Controlled Trial in Genotype 1 HCV-Infected Subjects to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Repeated Doses of TMC649128 Given as Monotherapy and Given in Combination With Pegylated Interferon + Ribavirin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tibotec BVBA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tibotec BVBA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine in genotype 1 Hepatitis C Virus (HCV)-infected&#xD;
      participants, the safety, tolerability, pharmacokinetics (how the drug is absorbed in the&#xD;
      body, how it is distributed within the body and removed from the body over time) and&#xD;
      antiviral activity of repeated doses of TMC649128 given as monotherapy and given in&#xD;
      combination with pegylated interferon + ribavirin. We assess the&#xD;
      pharmacokinetic/pharmacodynamic (how the study medication affects the body) (PK/PD)&#xD;
      relationship for antiviral activity, active metabolite and safety of TMC649128 and its&#xD;
      metabolites. We determine the short term safety and tolerability of the co-administration of&#xD;
      TMC649128 and pegylated interferon + ribavirin during multiple dosing for 14 days in&#xD;
      treatment-naive genotype 1 HCV-infected participants. We explore the effect of pegylated&#xD;
      interferon + ribavirin on the pharmacokinetics of TMC649128 during the multiple dosing for 14&#xD;
      days in treatment-naive genotype 1 HCV-infected participants. We also assess in a preliminary&#xD;
      way the short term antiviral effect of the combination of TMC649128 with pegylated interferon&#xD;
      + ribavirin during a 14-day dosing period in treatment-naive genotype 1 HCV-infected&#xD;
      participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TMC649128 is a nucleoside inhibitor (NI) of hepatitis C virus (HCV) polymerase in development&#xD;
      for the treatment of chronic hepatitis C infection. Treatment-naive genotype 1 HCV-infected&#xD;
      participants are participants who have never received (pegylated) interferon ([Peg]IFN),&#xD;
      ribavirin (RBV) or any other approved or investigational treatment for chronic HCV infection.&#xD;
      Treatment-experienced genotype 1 HCV-infected participants are defined as previous&#xD;
      non-responder and relapse subjects to previous treatment regimens (IFN/RBV or PegIFN/RBV),&#xD;
      who have never received a HCV polymerase inhibitor and HCV protease inhibitor treatment was&#xD;
      stopped since at least one year. This study is a Phase Ib, double-blind, randomized,&#xD;
      placebo-controlled trial in genotype 1 HCV-infected participants to determine the safety,&#xD;
      tolerability, pharmacokinetics and antiviral activity of repeated doses of TMC649128 given as&#xD;
      monotherapy and given in combination with pegylated interferon + ribavirin. This trial&#xD;
      consists of 2 phases. In the first phase TMC649128 will be given as monotherapy during 10&#xD;
      days at different doses and dosing regimens. In the second phase TMC649128 will be&#xD;
      administered at one selected dose regimen in combination with PegIFN a-2a/RBV for 14 days.;&#xD;
      All dosages of TMC649128 or placebo are given orally under fed conditions.; The monotherapy&#xD;
      phase includes 3 panels (panel 1-3) and the combination therapy phase includes 1 panel (panel&#xD;
      4). In panel 1, subjects are randomly assigned to receive TMC649128 at 1000 mg q24h (every&#xD;
      24h) (n=8) or placebo (n=2) q24h on Days 1-10. In panel 2 subjects are randomized into Arm 1&#xD;
      and Arm 2 and within each arm, subjects are randomly assigned to receive TMC649128 or placebo&#xD;
      as follows: In arm 1 volunteers receive TMC649128 at a selected dose (n=8) or placebo (n=2)&#xD;
      q12h on Days 1-10. In arm 2 volunteers receive TMC649128 at a selected dose (n=8) or placebo&#xD;
      (n=2) q24h on Days 1-10. Panel 3: TMC649128 at a selected dose (n=8) or placebo (n=2) q12h&#xD;
      (every 12h) OR q24h on Days 1-10 where the assignment is determined by randomization; Panel 4&#xD;
      volunteers are randomized into Arm 1 and Arm 2. In panel 4, arm 1, 10 volunteers receive&#xD;
      placebo (q12h OR q24h, dosing regimen matched to Arm 2 of Panel 4) + PegIFN a-2a/RBV on Days&#xD;
      1-14. In Panel 4, arm 2, 10 volunteers receive TMC649128 at a selected dose (q12h OR q24h) +&#xD;
      PegIFN a-2a/RBV on Days 1-14.; The actual dose of Panel 1 is derived from data obtained from&#xD;
      the currently ongoing MC649128HPC1001 trial. The actual dose in Panel 2 will depend on the&#xD;
      results of Panel 1 (total daily dose of TMC649128 administered in both arms of Panel 2 will&#xD;
      be the same. The dose of TMC649128 of the q24h regimen in Arm 2 will be higher than the q24h&#xD;
      dose administered in Panel 1 [1000 mg q24h]). The actual doses and dose regimens in Panels 3&#xD;
      and 4 will depend on the results of Panels 1 and 2 (data review meetings). Selection of doses&#xD;
      and dose regimens in Panels 2, 3 and 4 will also depend on the data obtained from trial&#xD;
      TMC649128HPC1001. Dosing will stay within the exposure limits. The intended doses for Panels&#xD;
      2 and 3 are 2000 mg or 3000 mg q12h or q24h, but may be adapted based on previous clinical&#xD;
      data. If needed and based on the outcome of the Panel 1 results, subjects in Panel 3 may&#xD;
      eventually receive a lower dose than in Panel 1. See detailed study description.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Antiviral activity was considered insufficient to warrant further clinical development of&#xD;
    TMC649128.&#xD;
  </why_stopped>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the steady-state plasma concentrations of TMC649128.</measure>
    <time_frame>From baseline up to Day 80 per panel (panel 1 + panel 2 + panel 3).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the steady-state plasma concentrations of TMC649128 following co-administration with pegylated interferon + ribavirin.</measure>
    <time_frame>From baseline up to day 84 (panel 4).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Viral load decreases and/or changes of viral load from baseline (HCV RNA copies/ml) (PK/PD).</measure>
    <time_frame>For monotherapy from baseline up to Day 80 per panel (panel 1 + panel 2 + panel 3) and for combination therapy from baseline up to day 84 (panel 4).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability - TMC649128 as monotherapy and when co-administered with pegylated interferon + ribavirin.</measure>
    <time_frame>For monotherapy from baseline up to Day 80 per panel (panel 1 + panel 2 + panel 3) and for combination therapy from baseline up to day 84 (panel 4).</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antiviral activity (HCV RNA levels) of TMC649128 as monotherapy and when co-administered with pegylated interferon + ribavirin.</measure>
    <time_frame>For monotherapy from baseline up to Day 80 per panel (panel 1 + panel 2 + panel 3) and for combination therapy from baseline up to day 84 (panel 4)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiviral activity (viral breakthrough) of TMC649128 as monotherapy and when co-administered with pegylated interferon + ribavirin.</measure>
    <time_frame>For monotherapy from baseline up to Day 80 per panel (panel 1 + panel 2 + panel 3) and for combination therapy from baseline up to day 84 (panel 4).</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Hepatitis C Virus</condition>
  <arm_group>
    <arm_group_label>010</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TMC649128 panel 4 arm 2: 10 participants receive PegIFN a-2a/RBV in combination with TMC649128 administered q12h or q24h for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1 2 and 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TMC649128. panel 1: 8 participants receive a q24h regimen at 1000 mg of TMC649128.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>002</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo. panel 1: 2 participants receive placebo at a q24h regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TMC649128. panel 2 arm 1: 8 participants receive a q12h regimen of TMC649128 at a selected dose based on results of panel 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>004</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo. panel 2 arm 1: 2 participants receive placebo at a q12h regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>005</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TMC649128. panel 2 arm 2: 8 participants receive a q24h regimen TMC649128 at a dose based on results of panel 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>006</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo. panel 2 arm 2: 2 participants receive placebo at a q24h regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>007</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TMC649128 panel 3: 8 participants receive TMC649128. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>008</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo. panel 3: 2 participants receive placebo. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>009</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo panel 4 arm 1: 10 participants receive PegIFN a-2a/RBV in combination with placebo administered q12h or q24h for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1 2 and 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo.</intervention_name>
    <description>panel 1: 2 participants receive placebo at a q24h regimen.</description>
    <arm_group_label>002</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo.</intervention_name>
    <description>panel 3: 2 participants receive placebo. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.</description>
    <arm_group_label>008</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TMC649128.</intervention_name>
    <description>panel 2, arm 1: 8 participants receive a q12h regimen of TMC649128 at a selected dose based on results of panel 1.</description>
    <arm_group_label>003</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo.</intervention_name>
    <description>panel 2, arm 2: 2 participants receive placebo at a q24h regimen.</description>
    <arm_group_label>006</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>panel 4, arm 1: 10 participants receive PegIFN a-2a/RBV in combination with placebo, administered q12h or q24h, for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1, 2 and 3.</description>
    <arm_group_label>009</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TMC649128</intervention_name>
    <description>panel 4, arm 2: 10 participants receive PegIFN a-2a/RBV in combination with TMC649128, administered q12h or q24h, for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1, 2 and 3.</description>
    <arm_group_label>010</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TMC649128.</intervention_name>
    <description>panel 2, arm 2: 8 participants receive a q24h regimen TMC649128 at a dose based on results of panel 1.</description>
    <arm_group_label>005</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TMC649128</intervention_name>
    <description>panel 3: 8 participants receive TMC649128. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.</description>
    <arm_group_label>007</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TMC649128.</intervention_name>
    <description>panel 1: 8 participants receive a q24h regimen at 1000 mg of TMC649128.</description>
    <arm_group_label>001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo.</intervention_name>
    <description>panel 2, arm 1: 2 participants receive placebo at a q12h regimen.</description>
    <arm_group_label>004</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented chronic (&gt; 6 months) genotype 1a or 1b Hepatitis C virus (HCV) infection&#xD;
&#xD;
          -  Treatment-naive volunteer, meaning never received (Peg)IFN, RBV or any other approved&#xD;
             or investigational treatment for chronic HCV infection (Panels 1, 2, 3 or 4) OR&#xD;
             volunteer is a documented prior non-responder or relapser subject to previous&#xD;
             treatment regimens (IFN/RBV or pegylated IFN/RBV) but has stopped this treatment at&#xD;
             least 6 months before screening&#xD;
&#xD;
          -  volunteer has never received a HCV polymerase inhibitor and HCV protease inhibitor&#xD;
             treatment was stopped since at least one year (Panels 1, 2 or 3)&#xD;
&#xD;
          -  Volunteer with HCV plasma RNA levels of &gt; 100,000 IU/mL at screening&#xD;
&#xD;
          -  Body Mass Index of 18.0 to 35.0 kg/m2&#xD;
&#xD;
          -  Healthy based on a medical evaluation including medical history, physical examination,&#xD;
             blood tests, vital signs, and electrocardiogram.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of liver cirrhosis&#xD;
&#xD;
          -  Historical liver biopsy graded as liver cirrhosis or evidence for the presence of&#xD;
             oesophageal varices or a transient elastography (Fibroscan) result of more than 14.6&#xD;
             kPa within 2 years prior to screening&#xD;
&#xD;
          -  Evidence of decompensated liver disease defined as prior history or current evidence&#xD;
             of ascites, hepatic encephalopathy, bleeding oesophageal or gastric varices&#xD;
&#xD;
          -  Evidence of renal dysfunction, documented by an estimated creatinine clearance below&#xD;
             70 mL/min&#xD;
&#xD;
          -  Evidence of any other cause of significant liver disease in addition to hepatitis C,&#xD;
             this may include but is not limited to hepatitis B, drug- or alcohol-related&#xD;
             cirrhosis, autoimmune hepatitis, hemochromatosis, Wilson's disease, non-alcoholic&#xD;
             steatohepatitis, or primary biliary cirrhosis&#xD;
&#xD;
          -  Volunteer with diagnosed or suspected hepatocellular carcinoma&#xD;
&#xD;
          -  Volunteer receiving or having received any treatment for HCV during the 6 months&#xD;
             before screening&#xD;
&#xD;
          -  Volunteer coinfected with Human Immunodeficiency Virus-1 (HIV-1) or HIV-2, or&#xD;
             hepatitis A or B virus infection, or clinically active tuberculosis at study&#xD;
             screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tibotec-Virco Virology BVBA Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Tibotec BVBA</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Zuidlaren</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krak√≥w</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>June 13, 2011</study_first_submitted>
  <study_first_submitted_qc>July 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2011</study_first_posted>
  <last_update_submitted>October 25, 2012</last_update_submitted>
  <last_update_submitted_qc>October 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TMC649128</keyword>
  <keyword>HCV</keyword>
  <keyword>TMC649128HPC1002</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>Hep C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

